Vaxneuvance Generic Name & Formulations
Pneumococcal 15-valent conjugate vaccine (diphtheria CRM197 protein); per 0.5mL; susp for IM inj; contains aluminum; preservative-free.
Single-dose prefilled syringes—1, 10
Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.
Vaxneuvance Dosage and Administration
Each dose is 0.5mL by IM inj. ≥18yrs: give 1 single dose.
Each dose is 0.5mL by IM inj. <6 weeks: not established. ≥6 weeks: 4-dose series given at 2, 4, 6, and 12–15 months of age (and at least 2 months after the 3rd dose). May give 1st dose as early as 6 weeks of age. Previously unvaccinated infants and children: 7–11 months of age: 3 doses (give 1st 2 doses at least 4 weeks apart, 3rd dose after 1st birthday and separated by at least 2 months after 2nd dose); 12–23 months of age: 2 doses at least 2 months apart; 2–17yrs of age: 1 single dose. Previously vaccinated with another pneumococcal conjugate vaccine: 2–17yrs of age: 1 single dose; at least 2 months should elapse between receiving the last dose of another pneumococcal conjugate vaccine and Vaxneuvance.
Allergies to any diphtheria toxoid-containing vaccine.
Vaxneuvance Boxed Warnings
Have appropriate medical treatment immediately available to manage allergic reactions. Immunocompromised. Premature infants. Pregnancy. Nursing mothers.
Immunosuppressants: may get suboptimal response.
Vaxneuvance Adverse Reactions
Inj-site pain/swelling/erythema, fatigue, myalgia, headache, arthralgia.
Vaxneuvance Clinical Trials
Vaxneuvance Patient Counseling